NCT04931329Active, not recruiting
Onco-haematology Vigilance Card
Impact of an Onco-haematology Vigilance Card in the Optimisation of the Town-hospital Relationship.
Source: ClinicalTrials.gov · Last updated 26 Jun 2026
Brief summary (registry, in English)
The objective of this study is to show the interest of setting up a drug vigilance card in Oncology in order to reinforce patient safety, develop compliance and avoid drug interactions when the patient consults town professionals or other specialists.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 10 May 2021
- Start date
- 8 Nov 2021
- Primary completion date
- 10 Jun 2024
- Lead sponsor
- University Hospital, Limoges
- Diseases
- Childhood cancers
- NCT number
- NCT04931329
What you commit to
- Study type: Observational
- Planned participants: 100
- From 8 Nov 2021 to the primary completion date, 10 Jun 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- All patients treated at Limoges University Hospital in Medical Oncology department, receiving hormone therapy or IV treatment only.
Who the study is looking for
- All patients treated at Limoges University Hospital in Medical Oncology department, receiving oral treatment (chemotherapy and/or targeted therapies)
Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU de Limoges Coordinator of this site? Confirm its status | Limoges | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.